• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did First-in-Class EU Approval for DAYBU Just Shift ACADIA Pharmaceuticals' (ACAD) Investment Narrative?

    Simply Wall St·08/28/2026 17:38:50
    Listen to the news
    • Acadia Pharmaceuticals has received European Commission marketing authorization for DAYBU (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in patients aged five and older across the European Union, Iceland, Liechtenstein, and Norway, based on Phase 3 LAVENDER data showing statistically significant and clinically meaningful improvements on key clinical scales.
    • This approval makes DAYBU the first and only authorized therapy for Rett syndrome in the EU, potentially opening a new rare-disease market while Acadia enters country-by-country pricing and reimbursement negotiations to convert regulatory success into commercial access.
    • We’ll now explore how DAYBU’s first-in-class EU approval for Rett syndrome could reshape Acadia’s investment narrative and long-term risk profile.

    Uncover the next big thing with 22 elite penny stocks that balance risk and reward.

    ACADIA Pharmaceuticals Investment Narrative Recap

    To own Acadia, you have to believe NUPLAZID and DAYBUE can together sustain profitable CNS and rare-disease franchises while the pipeline adds selective new revenue streams over time. The DAYBU EU approval strengthens the long term diversification story, but near term the key catalyst still looks like Alzheimer’s psychosis data from the RADIANT program, while heavy dependence on two commercial products remains the most important business risk.

    Among recent developments, the August 4 guidance raise stands out, with 2026 DAYBUE global sales now projected at US$480 million to US$510 million. The new EU authorization fits directly into that theme of broadening DAYBU’s reach, but it also underlines how much future execution will hinge on pricing and reimbursement outcomes in each country before those headline numbers can translate into durable revenue.

    Yet against this progress, investors should be aware that heavy reliance on NUPLAZID and DAYBUE still leaves Acadia exposed if...

    Read the full narrative on ACADIA Pharmaceuticals (it's free!)

    ACADIA Pharmaceuticals' narrative projects $1.7 billion revenue and $317.1 million earnings by 2029.

    Uncover how ACADIA Pharmaceuticals' forecasts yield a $33.25 fair value, a 12% upside to its current price.

    Exploring Other Perspectives

    ACAD 1-Year Stock Price Chart
    ACAD 1-Year Stock Price Chart

    Some of the most optimistic analysts were already assuming revenue could reach about US$1.9 billion and earnings around US$574 million, so this new EU approval might either reinforce their view of DAYBU as a global growth engine or highlight how much still depends on real world access and pricing, reminding you that reasonable people can look at the same data and reach very different conclusions.

    Explore 6 other fair value estimates on ACADIA Pharmaceuticals - why the stock might be worth over 3x more than the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    No Opportunity In ACADIA Pharmaceuticals?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.